Cytokine signaling--regulation of the immune response in normal and critically ill states.

Cytokines are produced during the activation of innate and acquired immunity, and are the principal means for intercellular communication of a microbial invasion. Cytokines serve to initiate the inflammatory response and to define the magnitude and the nature of the acquired immune response. The response of critically ill patients to their injury and/or invading pathogens is dependent, in large part, on the pattern of cytokines which are produced. The immunologic response of critically ill patients can vary from a strongly proinflammatory response, characterized by increased production of tumor necrosis factor-alpha, interleukin (IL)-1, interferon (IFN)-gamma, and IL-12 to one predominantly of anergy, characterized by increased production of T(H)2 cytokines, like IL-10 and to IL-4. Therapeutic efforts to modify the host immune response in critical illness will require a more thorough understanding of the cytokine milieu and the factors that determine their production.

[1]  P. Blackshear,et al.  Necrosis Factor Alpha Mrna Deadenylation and Destabilization of Tumor Au-rich Elements and Promotes the Evidence That Tristetraprolin Binds To , 1999 .

[2]  G. Kollias,et al.  Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. , 1999, Immunity.

[3]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[4]  I. Chaudry,et al.  Severe depression of host immune functions following closed-bone fracture, soft-tissue trauma, and hemorrhagic shock. , 1998, Critical care medicine.

[5]  R. Huber,et al.  Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Dinarello,et al.  Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. , 1997, Chest.

[7]  G. Zimmerman,et al.  Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. , 1997, The Journal of clinical investigation.

[8]  J. Mege,et al.  Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. , 1997, Critical care medicine.

[9]  J. Lederer,et al.  Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. , 1997, Annals of surgery.

[10]  U. Steckholzer,et al.  Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. , 1997, The Journal of trauma.

[11]  R. Kamen,et al.  Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN- γ production , 1997, Nature.

[12]  J. Kremer,et al.  Inhibition of the Defense System Stimulating Interleukin-12 Interferon-γ Pathway During Critical Illness , 1997 .

[13]  K. Asadullah,et al.  Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. , 1997, Archives of internal medicine.

[14]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[15]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[16]  R. Flavell,et al.  Polarization of IL-4- and IFN-gamma-producing CD4+ T cells following activation of naive CD4+ T cells. , 1997, Journal of immunology.

[17]  D. Klinman,et al.  Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. , 1996, Journal of immunology.

[18]  T. Standiford,et al.  Balance of inflammatory cytokines related to severity and mortality of murine sepsis , 1996, Infection and immunity.

[19]  H. Okamura,et al.  Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. , 1996, Cellular immunology.

[20]  H. Okamura,et al.  IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. , 1996, Journal of immunology.

[21]  R. Bone,et al.  Sir Isaac Newton, sepsis, SIRS, and CARS. , 1996, Critical care medicine.

[22]  M. Cuesta,et al.  Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. , 1996, Blood.

[23]  R. Locksley,et al.  The Instructive Role of Innate Immunity in the Acquired Immune Response , 1996, Science.

[24]  S. Beaucage,et al.  CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Dipiro,et al.  Interleukin-10 is associated with the development of sepsis in trauma patients. , 1996, The Journal of trauma.

[26]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[27]  R. Black,et al.  A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. , 1995, Journal of immunology.

[28]  G. Yancopoulos,et al.  Designer Cytokines: Targeting Actions to Cells of Choice , 1995, Science.

[29]  John A. Mannick,et al.  Major Injury Leads to Predominance of the T Helper‐2 Lymphocyte Phenotype and Diminished Interleukin‐12 Production Associated with Decreased Resistance to Infection , 1995, Annals of surgery.

[30]  S. Akira,et al.  Interleukin-6 family of cytokines and gp130. , 1995, Blood.

[31]  F. Schildberg,et al.  Downregulation of proinflammatory cytokine release in whole blood from septic patients. , 1995, Blood.

[32]  R. Black,et al.  A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes , 1995, The Journal of experimental medicine.

[33]  S. Dower,et al.  Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. , 1994, Journal of immunology.

[34]  C. Biron Cytokines in the generation of immune responses to, and resolution of, virus infection. , 1994, Current opinion in immunology.

[35]  E. Maggi,et al.  Human Th1 and Th2 cells: functional properties, mechanisms of regulation, and role in disease. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[36]  A. Mantovani,et al.  The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor , 1994, The Journal of experimental medicine.

[37]  P. Barie,et al.  Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. , 1994, Journal of the American College of Surgeons.

[38]  J. Jensenius,et al.  Collectins: collagenous C-type lectins of the innate immune defense system. , 1994, Immunology today.

[39]  D. Fearon,et al.  Innate immunity: 50 ways to kill a microbe. , 1994, Current opinion in immunology.

[40]  R. Bone,et al.  Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.

[41]  L. Tartaglia,et al.  Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. , 1993, The Journal of biological chemistry.

[42]  A. Drost,et al.  Plasma cytokines following thermal injury and their relationship with patient mortality, burn size, and time postburn. , 1993, The Journal of trauma.

[43]  A. Mantovani,et al.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. , 1993, Science.

[44]  M. Gayle,et al.  Interleukin 1 signaling occurs exclusively via the type I receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[45]  B. Barton,et al.  Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model , 1993, Infection and immunity.

[46]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[47]  I. Chaudry,et al.  Sepsis induces an early increased spontaneous release of hepatocellular stimulatory factor (interleukin-6) by Kupffer cells in both endotoxin tolerant and intolerant mice. , 1992, The Journal of surgical research.

[48]  I. Chaudry,et al.  Polymicrobial sepsis selectively activates peritoneal but not alveolar macrophages to release inflammatory mediators (interleukins-1 and -6 and tumor necrosis factor). , 1992, Circulatory shock.

[49]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[50]  Y. Vodovotz,et al.  Macrophage deactivation by interleukin 10 , 1991, The Journal of experimental medicine.

[51]  C. Dinarello,et al.  Interleukin-6 as an endogenous pyrogen: induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells , 1991, Brain Research.

[52]  T. Mosmann,et al.  IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. , 1991, Journal of immunology.

[53]  L. Gooding,et al.  A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact , 1990, Cell.

[54]  R. Ulevitch,et al.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. , 1990, Science.

[55]  J. Vilček,et al.  IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. , 1989, Journal of immunology.

[56]  K. Tracey,et al.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia , 1989, The Journal of experimental medicine.

[57]  L. Moldawer,et al.  Cachectin/tumor necrosis factor‐α alters red blood cell kinetics and induces anemia in vivo , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .

[59]  A. Waage,et al.  Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice , 1988, The Journal of experimental medicine.

[60]  T. Ikejima,et al.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. , 1988, The Journal of clinical investigation.

[61]  K. Tracey,et al.  Cytokine appearance in human endotoxemia and primate bacteremia. , 1988, Surgery, gynecology & obstetrics.

[62]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[63]  A. Forrest,et al.  Letter: Procaine and malignant hyperthermia. , 1974, Lancet.

[64]  G. Fantuzzi,et al.  Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). , 1999, Journal of clinical immunology.

[65]  C. Dinarello IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. , 1999, The Journal of allergy and clinical immunology.

[66]  S. Calvano,et al.  Trauma-induced alterations in macrophage function. , 1998, Surgery.

[67]  J. Kremer,et al.  Inhibition of the defense system stimulating interleukin-12 interferon-gamma pathway during critical Illness. , 1997, Blood.

[68]  K. Asadullah,et al.  Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. , 1997, Nature medicine.

[69]  R. Kamen,et al.  Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. , 1997, Nature.

[70]  G. Trinchieri Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. , 1995, Annual review of immunology.

[71]  R. Ulevitch,et al.  Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. , 1995, Annual review of immunology.

[72]  K. Tracey,et al.  Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. , 1994, Annual review of medicine.

[73]  H. Tilg,et al.  Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. , 1994, Blood.

[74]  M. Farrar,et al.  The molecular cell biology of interferon-gamma and its receptor. , 1993, Annual review of immunology.

[75]  P. Barie,et al.  Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. , 1990, Surgery, gynecology & obstetrics.

[76]  S. Akira,et al.  Biological and clinical aspects of interleukin 6. , 1990, Immunology today.

[77]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.

[78]  L. Moldawer,et al.  Cachectin: its impact on metabolism and nutritional status. , 1988, Annual review of nutrition.

[79]  P. Néve,et al.  Interleukin 2 , 1987, Acta clinica Belgica.